ArticleClinical epidemiology2026
Drug-Induced Orthostatic Hypotension in UK Primary Care: A Self-Controlled Case Series Study.
Article in Clinical epidemiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Drug-induced orthostatic hypotension (OH) is common and increasing worldwide with rising polypharmacy. Real-world evidence is crucial for safe prescribing. We examined the risk of OH associated with commonly prescribed drugs in UK primary care among adults aged ≥60 years. Methods: This was a self-controlled case series using routinely collected UK primary care data from the IQVIA Medical Research Database (IMRD). Individuals with an OH diagnosis and drug exposure between 1 January 2000 and 31 December 2018 were included. Drug classes potentially causing OH were coded by British National Formulary sub-chapters. Incidence rate ratios (IRRs) of OH were compared across a 90-day pre-exposure period and three post-prescription risk periods (day 1-28; day 29-56; day 57+) against periods outside these risk periods (reference period). Results: Of 2,597,077 eligible individuals, 41,005 (1.6%) had a first-recorded OH diagnosis; 51% were women. Increased OH risk was associated with initiation of all cardiovascular system (CVS), central nervous system (CNS), and urinary retention drugs, and some anti-diabetic drugs. Across most classes, OH risk peaked sharply after initiation (day 1-28) and then declined. Drugs causing OH via sympathetic inhibition, diuresis, or mixed mechanisms had the highest risk (eg, uroselective alpha-blockers: IRR 4.94, 95% CI 4.38-5.58) during day 1-28. Vasodilation-causing drugs had lower risk (eg, calcium-channel blockers: IRR 1.88, 95% CI 1.58-2.23). An increased OH risk was observed before drug initiation when the indication was an independent OH cause (eg, loop diuretics for heart failure: IRR 1.74, 95% CI 1.59-1.91). Conclusion: This study provides insights into OH risk across 17 drug classes in older adults, considering timing, drug system, and mechanism. Consistent trends show that OH risk peaked in the first 4 weeks post-initiation and reduced thereafter. Drugs causing OH through sympathetic inhibition, diuresis, or mixed mechanisms carried the greatest risk. Elevated OH risk in the pre-exposure period may suggest underlying indications that independently cause OH. These findings have important implications for primary care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.